Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Advanced BioHealing and Regenesis Biomedical have announced an agreement focused on the promotion of Dermagraft within the US government healthcare system.
Subscribe to our email newsletter
Under terms of the agreement Regenesis will provide its specialized sales force to market Advanced BioHealing’s product Dermagraft within the Veteran’s Administration (VA), Department of Defense (DOD), and TriCare healthcare payer systems.
Dermagraft is a bioengineered tissue product approved by the FDA for the treatment of diabetic foot ulcers.
Kevin Rakin, chairman and CEO of Advanced BioHealing, said: “The management team at Regenesis has developed a corporate competency in promoting and distributing advanced wound care technology within these systems. We believe this co-promotion is the most effective way to maximize reach and penetration of Dermagraft in this specialized market.”